Atherosclerosis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Atherosclerosis - Pipeline Review, H2 2016

Atherosclerosis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Atherosclerosis - Pipeline Review, H2 2016
Published Nov 09, 2016
252 pages — Published Nov 09, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis Pipeline Review, H2 2016, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 43 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 25 and 4 molecules, respectively.Atherosclerosis.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulat

  
Source:
Document ID
GMDHC8629IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents214
  List of Tables132
  List of Figures151
Introduction161
  Global Markets Direct Report Coverage161
Atherosclerosis Overview171
Therapeutics Development182
  Pipeline Products for Atherosclerosis Overview181
  Pipeline Products for Atherosclerosis Comparative Analysis191
Atherosclerosis Therapeutics under Development by Companies203
Atherosclerosis Therapeutics under Investigation by Universities/Institutes232
Atherosclerosis Pipeline Products Glance253
  Late Stage Products251
  Clinical Stage Products261
  Early Stage Products271
Atherosclerosis Products under Development by Companies284
Atherosclerosis Products under Investigation by Universities/Institutes322
Atherosclerosis Companies Involved in Therapeutics Development3439
  Ache Laboratorios Farmaceuticos S/A341
  advanceCor GmbH351
  AFFiRiS AG361
  Akcea Therapeutics Inc371
  Amgen Inc.381
  Arisaph Pharmaceuticals, Inc.391
  ARMO Biosciences, Inc.401
  Artery Therapeutics, Inc.411
  Athera Biotechnologies AB421
  Cardax, Inc.431
  Cerenis Therapeutics Holding SA441
  ChemoCentryx, Inc.451
  CohBar, Inc.461
  Daewoong Pharmaceutical Co., Ltd.471
  Daiichi Sankyo Company, Limited481
  DoNatur GmbH491
  Dybly AG501
  GenKyoTex S.A.511
  HitGen LTD521
  Jenrin Discovery, Inc.531
  Kang Stem Biotech Co., Ltd.541
  KineMed, Inc.551
  Kowa Company, Ltd.561
  La Jolla Pharmaceutical Company571
  Lead Discovery Center GmbH581
  LipimetiX Development Inc591
  Merck &Co., Inc.601
  Omeros Corporation611
  Otsuka Holdings Co., Ltd.621
  Resverlogix Corp.631
  The Medicines Company641
  Therapix Biosciences Ltd.651
  Tolerys SA661
  Unity Biotechnology, Inc.671
  Vascular Biogenics Ltd.681
  Vericel Corporation691
  Vicore Pharma AB701
  Vitae Pharmaceuticals, Inc.711
  XBiotech Inc721
Atherosclerosis Therapeutics Assessment7314
  Assessment by Monotherapy Products731
  Assessment by Combination Products741
  Assessment by Target754
  Assessment by Mechanism of Action794
  Assessment by Route of Administration832
  Assessment by Molecule Type852
Drug Profiles87133
  2-CCPA Drug Profile871
  AEM-28 Drug Profile882
  AM-0010 Drug Profile903
  anacetrapib Drug Profile932
  Annexin A-5 Drug Profile951
  apabetalone Drug Profile9610
  APTA-5278 Drug Profile1061
  ARI-1778 Drug Profile1071
  ATH-04 Drug Profile1081
  ATH-06 Drug Profile1091
  BSN-272 Drug Profile1101
  C-21 Drug Profile1112
  CCX-771 Drug Profile1131
  CDX-085 Drug Profile1142
  Cell Therapy for Atherosclerosis Drug Profile1161
  Cellular Immunotherapy for Atherosclerosis Drug Profile1171
  CER-209 Drug Profile1181
  CM-7 Drug Profile1191
  COR-2 Drug Profile1201
  D-4F Drug Profile1211
  DIAS-2 Drug Profile1221
  Dipep Drug Profile1231
  Drug for Atherosclerosis Drug Profile1241
  Drug for Atherosclerosis Drug Profile1251
  Drugs to Activate TLR3 for Atherosclerosis Drug Profile1261
  DWJ-210 Drug Profile1271
  DYB-186 Drug Profile1281
  ecraprost Drug Profile1292
  EP-80317 Drug Profile1311
  Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis Drug Profile1321
  Gene Therapy to Activate Interleukin 10 for Atherosclerosis Drug Profile1331
  Gene Therapy to Activate Telomerase for Alzheimer s Disease and Atherosclerosis Drug Profile1341
  GKT-831 Drug Profile1353
  GYY-4137 Drug Profile1381
  Humanin Drug Profile1391
  IMMH-007 Drug Profile1401
  INV-88 Drug Profile1411
  IONIS-APOARX Drug Profile1423
  ITP-01 Drug Profile1451
  ixmyelocel-T Drug Profile1466
  JD-2000 Series Drug Profile1521
  JD-5000 Series Drug Profile1531
  JD-6000 Series Drug Profile1541
  K-312 Drug Profile1551
  KM-011 Drug Profile1561
  leucine + niacin Drug Profile1571
  liothyronine Drug Profile1581
  LJPC-6417 Drug Profile1591
  LPC-01 Drug Profile1601
  MCC-950 Drug Profile1611
  MCS-18 Drug Profile1622
  MDCO-216 Drug Profile1643
  melittin Drug Profile1671
  Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis Drug Profile1681
  Oligonucleotide for Hyperlipidemia and Atherosclerosis Drug Profile1691
  P-16 Drug Profile1701
  PC-mAb Drug Profile1712
  PDI-41 Drug Profile1731
  pemafibrate Drug Profile1742
  Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis Drug Profile1761
  Recombinant Protein for Atherosclerosis and Hepatic Steatosis Drug Profile1771
  Recombinant Protein for Cardiovascular Diseases Drug Profile1781
  Recombinant Proteins for Atherosclerosis, Ischemic Stroke and Thrombosis Drug Profile1791
  Small Molecule for Atherosclerosis Drug Profile1801
  Small Molecule for Atherosclerosis and Hyperlipidemia Drug Profile1811
  Small Molecule for Atherosclerosis and Insulin Resistance Drug Profile1821
  Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology Drug Profile1831
  Small Molecule to Agonize Liver X Receptor for Atherosclerosis Drug Profile1841
  Small Molecule to Agonize LXRB for Atherosclerosis Drug Profile1851
  Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders Drug Profile1861
  Small Molecule to Inhibit microRNA-223 for Atherosclerosis Drug Profile1871
  Small Molecule to Target GPR132 for Cardiovascular Diseases Drug Profile1881
  Small Molecules for Atherosclerosis Drug Profile1891
  Small Molecules for Atherosclerosis Drug Profile1901
  Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity Drug Profile1911
  Small Molecules to Inhibit Chymase for Atherosclerosis Drug Profile1921
  Small Molecules to Inhibit Lipase for Atherosclerosis Drug Profile1931
  Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis Drug Profile1941
  Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders Drug Profile1952
  SPX-7233801 Drug Profile1971
  SR-9009 Drug Profile1981
  Stem Cell Therapy for Atherosclerosis Drug Profile1991
  Stem Cell Therapy for Osteoarthritis, Atherosclerosis and Arteriosclerosis Obliterans Drug Profile2001
  SURE-NAC Drug Profile2011
  Synthetic Peptide to Inhibit F11R for Atherosclerosis Drug Profile2022
  Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease Drug Profile2041
  Synthetic Peptides for Oncology, Sepsis and Atherosclerosis Drug Profile2051
  Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation Drug Profile2061
  Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration Drug Profile2072
  TRX-318 Drug Profile2092
  TT-301 Drug Profile2111
  Vaccine for Atherosclerosis Drug Profile2121
  Vaccine for Atherosclerosis Drug Profile2131
  Vaccine for Atherosclerosis Drug Profile2141
  Vaccine for Autoimmune Disease, Cardiovascular Disease, Immunology, Infectious Disease and Oncology Drug Profile2151
  VB-201 Drug Profile2163
  VTP-4 Drug Profile2191
Atherosclerosis Dormant Projects22012
Atherosclerosis Discontinued Products2323
Atherosclerosis Product Development Milestones23516
  Featured News &Press Releases2351
    Aug 30, 2016: The Medicines Company Provides Update on MDCO-2162351
    Feb 25, 2016: Cerenis Therapeutics featured prominently at the 25th Conference of the ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER (APASL)2351
    Jan 25, 2016: Resverlogix Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal2361
    Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy2362
    Jul 22, 2015: Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet2381
    Jun 18, 2015: Cardax Initiates Monkey Study to Compare Bioavailability of Patented Consumer Health Product Candidate CDX-085 to Microalgal Astaxanthin2391
    Mar 11, 2015: The Medicines Company Provides new data on MDCO-216 at 2015 American College of Cardiology Scientific Sessions in San Diego2391
    Jan 07, 2015: Interleukin Announces Collaboration with Isis Pharmaceuticals for Genetic Testing Services2401
    Nov 14, 2014: The Medicines Company to Present New Data on Investigational Lipid-Modifying Agent MDCO-216 at 2014 AHA Annual Scientific Sessions in Chicago2401
    May 21, 2014: Resverlogix Corporation Release: Leading Life Science Publication SciBX Highlights RVX-2082411
    May 19, 2014: Recent Studies Further Demonstrate Astaxanthin s Potential As A Safe And Effective Anti-Inflammatory2425
    Mar 31, 2014: Cleveland Clinic Presents RVX-208 Data at American College of Cardiology Conference2471
    Mar 17, 2014: Resverlogix Receives European Patent For RVX-2082481
    Jan 15, 2014: Resverlogix Announces Combined RVX-208 findings from SUSTAIN &ASSURE Phase 2b Trials2491
    Jan 02, 2014: Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist2492
Appendix2512
  Methodology2511
  Coverage2511
  Secondary Research2511
  Primary Research2511
  Expert Panel Validation2511
  Contact Us2511
  Disclaimer2521

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Atherosclerosis - Pipeline Review, H2 2016" Nov 09, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Atherosclerosis-Pipeline-Review-H2-2016-2088-16758>
  
APA:
Global Markets Direct - Market Research. (2016). Atherosclerosis - Pipeline Review, H2 2016 Nov 09, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Atherosclerosis-Pipeline-Review-H2-2016-2088-16758>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.